A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven‐day storage

Therapeutic phlebotomy is the standard treatment of hereditary hemochromatosis (HH), the most common genetic disease in people of Northern European descent. Red cell concentrates from HH donors have been reported safe for transfusion, but little data is available on the storage properties of platelet concentrates from HH donors.

[1]  Sara C Lewis,et al.  Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI , 2018, Expert review of gastroenterology & hepatology.

[2]  T. Schiano,et al.  Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis , 2017, Hepatology.

[3]  C. McLaren,et al.  Haemochromatosis , 2018, Nature Reviews Disease Primers.

[4]  P. Tiberghien,et al.  Properties of donated red blood cell components from patients with hereditary hemochromatosis , 2017, Transfusion.

[5]  K. Annen,et al.  Optimizing platelet transfusions , 2015, Current opinion in hematology.

[6]  D. Deeren,et al.  Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions , 2015, Transfusion.

[7]  R. Kaur,et al.  Platelet storage lesion: An update , 2015, Asian journal of transfusion science.

[8]  A. Greinacher,et al.  Platelet transfusion in hematology, oncology and surgery. , 2014, Deutsches Arzteblatt international.

[9]  V. Compernolle,et al.  Worldwide policies on haemochromatosis and blood donation: a survey among blood services , 2013, Vox sanguinis.

[10]  G. Soslau,et al.  Iron levels found in hemochromatosis patients inhibit γ-thrombin-induced platelet aggregation , 2012, Platelets.

[11]  V. Compernolle,et al.  Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion? A systematic review. , 2012, Journal of hepatology.

[12]  V. Vicente,et al.  Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system. , 2012, Blood transfusion = Trasfusione del sangue.

[13]  C. Morrell,et al.  Recently recognized platelet agonists , 2011, Current opinion in hematology.

[14]  H. Ohto,et al.  Overview on platelet preservation: better controls over storage lesion. , 2011, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[15]  P. Sandgren,et al.  Storage of buffy-coat-derived platelets in additive solution: in vitro effects on platelets of the air bubbles and foam included in the final unit. , 2011, Blood transfusion = Trasfusione del sangue.

[16]  K. Silva,et al.  Platelet aggregation and quality control of platelet concentrates produced in the Amazon Blood Bank , 2011, Revista brasileira de hematologia e hemoterapia.

[17]  D. Devine,et al.  The platelet storage lesion. , 2010, Clinics in laboratory medicine.

[18]  N. Blumberg,et al.  Platelet transfusions: trigger, dose, benefits, and risks , 2010, F1000 medicine reports.

[19]  O. Azizova,et al.  Effect of Iron Ions on Functional Activity of Thrombin , 2009, Bulletin of Experimental Biology and Medicine.

[20]  M. Shrivastava.  The platelet storage lesion. , 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[21]  H. Ohto,et al.  Survival and recovery of apheresis platelets stored in a polyolefin container with high oxygen permeability , 2008, Vox sanguinis.

[22]  P. Hellstern,et al.  Preservation of platelet aggregation and dense granule secretion during extended storage of blood samples in the presence of a synthetic dual inhibitor of factor Xa and thrombin , 2008, Platelets.

[23]  C. Prowse,et al.  Extended storage of platelets in SSP+ platelet additive solution , 2006, Vox sanguinis.

[24]  R. Kaufman.  Platelets: testing, dosing and the storage lesion--recent advances. , 2006, Hematology. American Society of Hematology. Education Program.

[25]  M. Wadhwa,et al.  In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools , 2005, Vox sanguinis.

[26]  Harprit Singh,et al.  Evaluation of platelet storage lesions in platelet concentrates stored for seven days. , 2003, The Indian journal of medical research.

[27]  W. Sly,et al.  Human platelets express hemochromatosis protein (HFE) and transferrin receptor 2 , 2003, European journal of haematology.

[28]  G. Tonon,et al.  Weak platelet agonists and U46619 induce apoptosis-like events in platelets, in the absence of phosphatidylserine exposure. , 2002, Thrombosis research.

[29]  C. Seamark,et al.  Should asymptomatic haemochromatosis be treated? , 2000, BMJ : British Medical Journal.

[30]  Veldman,et al.  Comparison between a new PVC platelet storage container (UPX80) and a polyolefin container , 2000, Transfusion medicine.

[31]  C. Seamark,et al.  Should asymptomatic haemochromatosis be treated?Treatment can be onerous for patient and doctorCommentary: False certainty of clinical guidanceCommentary: Early treatment is essential , 2000 .

[32]  M. Bins,et al.  Improvement of platelet storage conditions by using new polyolefin containers , 1997, Transfusion.

[33]  H. Weiss,et al.  Heterogeneous defects of platelet secretion and responses to weak agonists in patients with bleeding disorders , 1988, British journal of haematology.

[34]  S. Murphy,et al.  Platelet storage at 22 degrees C: effect of type of agitation on morphology, viability, and function in vitro , 1978 .

[35]  F. Gardner,et al.  Platelet storage at 22 degrees C: role of gas transport across plastic containers in maintenance of viability. , 1975, Blood.